Baxter International (BAX)
(Delayed Data from NYSE)
$35.54 USD
+1.57 (4.62%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $35.57 +0.03 (0.08%) 5:16 PM ET
2-Buy of 5 2
A Value C Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Baxter International Inc. [BAX]
Reports for Purchase
Showing records 161 - 180 ( 509 total )
Company: Baxter International Inc.
Industry: Medical - Products
Comprehensive Technical and Fundamental Analysis for BAX.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Comprehensive Technical and Fundamental Analysis for BAX.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
MedTech 2022 Outlook An Early Dodgeball Story
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Remain Focused on LT Opportunity for the Combined BAX/HRC Portfolio
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Relatively Stable Quarter Likely a Positive
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Baxter International Inc.
Industry: Medical - Products
Company: Baxter International Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department